Janneke de Wal
Nessuna posizione attualmente
Provenienza dei contatti di primo grado di Janneke de Wal
| Entità | Tipo di entità | Settore Industriale | |
|---|---|---|---|
University of Leiden
36
| College/University | Other Consumer Services | 36 |
Amsterdam Molecular Therapeutics (AMT) Holding NV
 Amsterdam Molecular Therapeutics (AMT) Holding NV Miscellaneous Commercial ServicesCommercial Services Amsterdam Molecular Therapeutics (AMT) Holding NV engages in the development of human gene based therapies. The company has a product pipeline of several gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. It is expected to be finally dissolved in September 2012. Amsterdam Molecular Therapeutics (AMT) Holding was founded by Sander J. H. van Deventer and John J. P. Kastelein on March 20, 1998 and is headquartered in Amsterdam, Netherlands.
21
| Extinct | Miscellaneous Commercial Services | 21 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Janneke de Wal tramite i suoi contatti personali
| Società | Settore | Persone collegate | Posizione principale |
|---|---|---|---|
| BIOGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal Sales & Marketing | |
| Gene Therapy Systems, Inc. | Director/Board Member | ||
| BROOKS MACDONALD GROUP PLC | Investment Managers | Chairman | |
Celgene International SARL
 Celgene International SARL Pharmaceuticals: MajorHealth Technology Founded in 2010, Celgene International SARL is a Swiss bio-pharmaceutical company that operates to discover, develop, and commercialize therapies for unmet medical needs in cancer. Part of Bristol Myers Squibb Co., the company is based in Boudry, Switzerland. | Pharmaceuticals: Major | President | |
| JUPITER FUND MANAGEMENT PLC | Investment Trusts/Mutual Funds | Chief Executive Officer | |
Jupiter Asset Management Ltd.
 Jupiter Asset Management Ltd. Investment ManagersFinance Jupiter Asset Management Ltd. (JAM) is an investment management firm headquartered in London, UK. The firm was founded in 1985 and is a subsidiary of Jupiter Investment Management Group Ltd., ultimately owned by Jupiter Fund Management plc (LON: JUP). They were previously a subsidiary of Commerzbank AG until 2007 when their senior management acquired the firm through a management buyout. The firm offers a range of actively managed strategies available to UK and international clients including equities, fixed income, multi-asset and alternatives. JAM is a signatory on a number of key initiatives such as the UN Principles for Responsible Investment. | Investment Managers | Chief Executive Officer | |
| ROLINCO N.V. | Investment Trusts/Mutual Funds | Chairman | |
| THE LAW DEBENTURE CORPORATION P.L.C. | Investment Trusts/Mutual Funds | Director/Board Member | |
IsoTis NV
 IsoTis NV BiotechnologyHealth Technology IsoTis NV manufactures, markets and sells a range of bone graft substitutes and other related medical devices. These devices are used to enhance the repair and regeneration of bone in spinal and trauma surgery, joint replacements and dental applications. IsoTis' products are primarily used spinal fusion, trauma, joint revision, bone void filling and iliac crest backfills procedures. The company is headquartered in Bilthoven, the Netherlands | Biotechnology | President Founder | |
| ROBECO HOLLANDS BEZIT | Investment Trusts/Mutual Funds | Chairman | |
Prime Technology Ventures NV
 Prime Technology Ventures NV Investment ManagersFinance Prime Technology Ventures NV (Prime Ventures) is the venture capital firm, a subsidiary of Prime Technology Venture Partners BV founded in 1999 by Sake Bosch. Prime Technology Ventures BV is headquartered in Amseterdam, the Netherlands. | Investment Managers | Private Equity Investor Private Equity Investor | |
| University of Cambridge | College/University | Graduate Degree Undergraduate Degree | |
BASF Performance Products Ltd. (United Kingdom)
 BASF Performance Products Ltd. (United Kingdom) Chemicals: SpecialtyProcess Industries Basf Performance Products Ltd. manufactures chemical products. It offers dyes and pigments, plastics, and other inorganic basic chemicals. The company was founded on September 12, 1996 and is headquartered in Cheadle, the United Kingdom. | Chemicals: Specialty | Corporate Officer/Principal | |
AlpInvest Partners BV
 AlpInvest Partners BV Investment ManagersFinance AlpInvest Partners BV (AlpInvest) is a private equity asset subsidiary AP BV, ultimately owned by The Carlyle Group, Inc founded in 2000. AlpInvest Partners BV is headquartered in Amsterdam, the Netherlands. | Investment Managers | Chief Executive Officer Private Equity Investor | |
Rhone Poulenc Rorer
 Rhone Poulenc Rorer Chemicals: SpecialtyProcess Industries Part of Solvay SA, Rhone Poulenc Rorer is a French pharmaceutical company that manufactures and distributes pharmaceutical products. | Chemicals: Specialty | Chief Tech/Sci/R&D Officer | |
CropDesign NV
 CropDesign NV Miscellaneous Commercial ServicesCommercial Services CropDesign NV develops traits for cereal crops. It delivers agronomic traits for the global commercial seed markets. The firm focuses on enhancing grain yield in crops such as corn and rice, and increasing biomass of energy crops. Its platform, TraitMill, lows evaluating the effect of genes on the performance of plants under different growing conditions, including drought and low nutrient stress. The company was founded in 1998 and is headquartered in Zwijnaarde, Blgium. | Miscellaneous Commercial Services | Corporate Officer/Principal Founder | |
| University of Amsterdam | College/University | Graduate Degree Graduate Degree Doctorate Degree Undergraduate Degree Graduate Degree | |
| University of Groningen | College/University | Doctorate Degree Undergraduate Degree | |
| University of Giessen | College/University | Doctorate Degree | |
Maetis BV
 Maetis BV Miscellaneous Commercial ServicesCommercial Services Part of Joseph Beuys GmbH, Maetis BV provides business consulting services such as providing working conditions and reintegration services. The company is based in Houten, Netherlands. Maetis was acquired by Joseph Beuys GmbH from PGGM Vermogensbeheer BV on October 07, 2005. | Miscellaneous Commercial Services | President | |
| University of Zurich | College/University | Doctorate Degree | |
| GENMED HOLDING CORP. | Pharmaceuticals: Generic | Chief Operating Officer | |
Forbion Capital Partners Management Holding BV
 Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Investment Managers | Private Equity Investor Founder Private Equity Investor | |
| MOLECULAR PARTNERS AG | Biotechnology | Director/Board Member Chairman | |
New Europe Ventures LLC
 New Europe Ventures LLC Investment ManagersFinance New Europe Ventures LLC (New Europe Ventures) is a venture capital firm founded in 2006 by Martin Jasinski and Andrew Rasiej. The firm is headquartered in New York. | Investment Managers | Consultant / Advisor | |
Solvay Pharmaceuticals SA
 Solvay Pharmaceuticals SA Pharmaceuticals: MajorHealth Technology Solvay Pharmaceuticals SA develops, manufactures, and supplies pharmaceutical products. The company's products include cardio-metabolics, influenza vaccines, adjuvants, and women's and men's healthcare products. It offers fenofibrate, a cardio-metabolic product for treating raised blood lipids and dyslipidemia products that control cholesterol and triglycerides. The firm is headquartered in Brussels, France. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Oxyrane UK Ltd.
 Oxyrane UK Ltd. Pharmaceuticals: MajorHealth Technology Oxyrane UK Ltd. engages in the development of novel enzyme replacement therapies for lysosomal storage disorders. Its product is a pre-clinical ERT for Pompe Disease - a serious muscle disease - produced using engineered yeast cells. The firm develops recombinant enzyme products using a proprietary, engineered yeast expression platform based on Yarrowia lipolytica. The company was founded by Robin Kumar Mitra, Adriana L. Botes and Michael Campbell in 2006 and is headquartered in Manchester, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Amgen Europe BV
 Amgen Europe BV Medical DistributorsDistribution Services Part of Amgen, Inc., Amgen Europe BV wholesales pharmaceutical products. The company is based in Breda, Netherlands. | Medical Distributors | Corporate Officer/Principal | |
Centre National de la Recherche Scientifique
 Centre National de la Recherche Scientifique General GovernmentGovernment Centre National de la Recherche Scientifique provides scientific research services. The firm engages in the research capable of advancing knowledge and bringing social, cultural, and economic benefits for society. The company was founded in 1939 and is headquartered in Paris, France. | General Government | Chief Tech/Sci/R&D Officer | |
| Stichting Volksgezondheid en Milieu | Investment Trusts/Mutual Funds | Corporate Officer/Principal | |
| De Witte Raaf Arbodienst BV | Chief Executive Officer | ||
| Sociaal Gezondheids Vereniging | Corporate Officer/Principal | ||
Hookipa Biotech AG
 Hookipa Biotech AG Medical SpecialtiesHealth Technology Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria. | Medical Specialties | Chief Executive Officer Director/Board Member | |
| UNIQURE N.V. | Biotechnology | Director/Board Member Chairman Chief Executive Officer Founder Founder Chief Executive Officer Director/Board Member Chief Tech/Sci/R&D Officer Chief Operating Officer Director/Board Member Chief Tech/Sci/R&D Officer | |
| Rotterdam School of Management | College/University | Masters Business Admin Doctorate Degree | |
| PROQR THERAPEUTICS N.V. | Pharmaceuticals: Major | Founder Director of Finance/CFO Founder | |
Silver Arrow Capital Management Ltd.
 Silver Arrow Capital Management Ltd. Investment ManagersFinance Silver Arrow Capital Management Ltd. provides financial analyzing and consulting services for gold mining companies. The private company is based in London, UK. The British company was founded by Gijsbert Groenewegen and he has been the CEO since incorporation. | Investment Managers | Chief Executive Officer | |
DegenRx BV
 DegenRx BV BiotechnologyHealth Technology DegenRx BV is a Dutch biotech company that is focused on developing AAV-mediated gene therapy for the treatment of CNS diseases such as Alzheimer's and Parkinson's disease. The company is based in Tilburg, Netherlands. The company aims to address the lack of drugs available to stop or slow down the progression of Alzheimer's disease, which affects about two-thirds of the 50 million people reported to suffer from dementia worldwide. One of the approaches most advanced in clinical studies is immunotherapy against amyloid beta, which DegenRx is working on. Inez de Greef-van der Sand has been the CEO of the company since 2020. | Biotechnology | Corporate Officer/Principal | |
| HOOKIPA PHARMA INC. | Biotechnology | Chief Executive Officer Director/Board Member | |
VectorY BV
 VectorY BV Miscellaneous Commercial ServicesCommercial Services VectorY BV is a biotech company based in Amsterdam, Netherlands, that is dedicated to developing transformative medicines for people with neurodegenerative diseases such as ALS, Huntington's, and Parkinson's. VectorY's platform combines the promise of precise therapeutic antibodies with one-time AAV-based delivery to the CNS, enabling long-lasting CNS treatment after a single administration using cutting-edge antibody, AAV, and manufacturing technologies. The Dutch company's unique in-house expertise in antibodies, AAV vectors, protein degradation, manufacturing, and neuroscience drives the rapid development of much-needed disease-modifying therapies for neurodegenerative diseases. The company was founded by Sander J. van Deventer and Pavlina Konstantinova, with Sander J. van Deventer serving as the CEO since incorporation. | Miscellaneous Commercial Services | Chief Executive Officer Director/Board Member | |
| AMERICAN EAGLE GOLD CORP. | Precious Metals | Director/Board Member | |
| REGENCY SILVER CORP. | Precious Metals | Founder | |
| The Gold Arrow Fund | Founder | ||
Mintus Group Ltd
 Mintus Group Ltd Packaged SoftwareTechnology Services Mintus Group Ltd provides access to alternative asset classes for family offices, uhnws, institutions, and qualifying mass affluent investors. The company is based in London, UK, and has subsidiaries in the UK. The British company aims to improve portfolio diversification and enhance risk-adjusted returns in a challenging geo-political and economic environment. Mintus operates on an advanced platform that utilizes cutting-edge technology to facilitate efficient scaling and provide a seamless investor experience in digital assets. The company applies AI capability to asset selection across various asset classes. Mintus operates in a regulated environment, ensuring transparency and building trust through its PE grade investment committee and asset selection and exit process. Additionally, Mintus offers fractionalization of the fine-art market, allowing investors to buy and sell the world's greatest art. The Mintus art investment committee, consisting of experts with over 150 years of combined experience in the art market and financial industries, selects the artworks offered to investors. The company was founded in 2020 by Tamer Ozmen, who has been the CEO since 2020. | Packaged Software | Chairman | |
NewAmsterdam Pharma BV
 NewAmsterdam Pharma BV Pharmaceuticals: MajorHealth Technology NewAmsterdam Pharma BV develops novel drugs to treat dyslipidemia. It operates as a biotechnology company and develops anti-dyslipidemic compounds in cardiovascular disease indications. The firm's product DEZ-001 develops a potent cholesteryl ester transfer protein inhibitor that has shown a decrease of low-density lipoprotein levels, and an increase of high-density lipoprotein levels. The company was founded by John J. P. Kastelein in 2012 and is headquartered in Naarden, the Netherlands. | Pharmaceuticals: Major | Founder Chairman |
Statistiche
Distribuzione geografica
| Paesi Bassi | 20 |
| Regno Unito | 11 |
| Stati Uniti | 7 |
| Svizzera | 4 |
| Francia | 4 |
Settori
| Health Technology | 16 |
| Finance | 10 |
| Consumer Services | 7 |
| Miscellaneous | 6 |
| Commercial Services | 5 |
Posizioni
| Director/Board Member | 255 |
| Corporate Officer/Principal | 94 |
| Chairman | 53 |
| Chief Executive Officer | 46 |
| Founder | 43 |
Contatti più connessi
| Insiders | |
|---|---|
| Hugo Slootweg | 34 |
| Patrick Volkert Vink | 30 |
| Steven Holtzman | 28 |
| Ferdinand Verdonck | 25 |
| Joseph Feczko | 23 |
| Bote de Vries | 22 |
| François Meyer | 20 |
| Joost Hessel Louis Bergsma | 19 |
| Steven van Groningen | 18 |
| Piers John Morgan | 18 |
| Sander J. van Deventer | 17 |
| George Morstyn | 17 |
| Pieter Wolters | 15 |
| Jaap Tonckens | 15 |
| Domenico Valerio | 15 |
- Borsa valori
- Insiders
- Janneke de Wal
- Connessioni Società
